99
- ASTRO 2025: Safety and Efficacy of POstoPerative Ablative RadioTherapy (POPART) for Post-Prostatectomy Biochemical Recurrence UroToday
- Radiopharmaceutical added to stereotactic radiation can delay prostate cancer progression Medical Xpress
- ASTRO 2025: Phase III Study of Hypofractionated, Dose Escalation Radiotherapy vs. Conventional Pelvic Radiation Therapy followed by High Dose Rate Brachytherapy Boost for High-Risk Adenocarcinoma of the Prostate (PCS VI) UroToday
- MiraDx Announces New Research Conducted by UCLA and Other Academic Centers Presented at ASTRO 2025 that Confirms that Prostate Cancer Patients Identified as High-risk with PROSTOX™ ultra for SBRT Toxicity Can Safely Receive Other Radiation R Yahoo Finance
- ASTRO: Targeted Radioactive Therapy, New SBRT Approaches, 5DCT-Guided Imaging and More Oncodaily
